Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It’s available as an extended-release oral tablet and ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...

Shares of AbbVie ABBV rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...

Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

AbbVie said a late-stage study of its blockbuster autoimmune drug Rinvoq hit its key goals in alopecia areata, an autoimmune disease that causes sudden hair loss. AbbVie on Wednesday said the Phase 3 ...